Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc.

Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc.


It appears from the phase 3 data that volanesorsen should be able to get approved. It's not a perfect drug -- it has some side effects -- but the risk-benefit profile looks strong enough to gain approval, especially given the unmet need in patients with rare diseases -- familial partial lipodystrophyand familial chylomicronemia syndrome -- that cause severely high triglyceride levels, which Ionis is going after.



from Biotech News